Both a protective and a deleterious role for the L76V mutation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1724-1725

  Tartaglia, Alessandra ^a   Saracino, Annalisa ^a   Monno, Laura ^b   Tinelli, Carmine ^c   Angarano, Gioacchino ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; INDINAVIR; LOPINAVIR; SAQUINAVIR; TIPRANAVIR;

DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

EID: 65649094122     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01693-08     Document Type: Letter

References (9)

1. Baxter, J. D., J. M. Schapiro, C. A. Boucher, V. M. Kohlbrenner, D. B. Hall,J. R. Scherer, and D, L, Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801. (Pubitemid 44628925)
2. de Mendoza, C, C. Garrido, A. Corral, N. Zahonero, and V. Soriano. 2008. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. AIDS 22:311-313.
3. de Meyer, S., T. Vangeneugden, B. van Baelen, E. de Paepe, H. van Marck, G. Picchio, E. Lefebvre, and M. P. de Bethune. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retrovir. 24:379-388.
4. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman-2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:62-68.
5. Lambert-Niclot, S., P. Flandre, A. Canestri, G. Peytavin, C. Blanc, R. Agher, C. Soulie, M. Wirden, C. Katlama, V. Calvez, and A. G. Marcelin. 2008. Factors associated with the selection of mutations conferring resistance to protease inhibitors (Pis) in Pi-experienced patients displaying treatment failure on darunavir. Antimicrob. Agents Chemother. 52:491-496.
6. Mueller, S. M., M. Daeumer, R. Kaiser, H. Walter, R. Colonno, P. Braun, and K, Korn, 2004. Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI)-resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V, abstr. 38. Abstr. 13th Int. HIV Drug Resist. Workshop.
7. Norton, M., T. Young, N. Parkin, D. Tokimoto, L. Lu, T. Piot-Matias, E. Stawiski, K. Stewart, D. Kempf, and S. Rahim. 2008. Prevalence, mutational patterns and phenotypic correlates of the L76V protease mutation in relation to LPV-associated mutations, abstr. 854. Abstr. 15th Conf. Retrovir. Opportunistic Infect.
8. Parkin, L., and C. Chappey. 2006. Protease mutations associated with a higheror lower than expected tipranavir (TPV) susceptibility based on the TPV mutation score, abstr. 637. Abstr. 13th Conf. Retrovir. Opportunistic Infect.
9. Scherer, J., C. A. Boucher, J. D. Baxter, J. M. Schapiro, V. M. Kohlbrenner,and D. B. Hall, 2007. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score, poster P3.4/07. 11th Eur. AIDS Conf. Soc.